



RECEIVED

OCT 18 2002

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary) <i>15</i>		Application Number	<i>10/004,105</i>
		Filing Date	<i>12/04/2001</i>
		First Named Inventor	<i>Thomas Slaga</i>
		Group Art Unit	<i>1614</i>
		Examiner Name	<i>Unknown</i>
		Attorney Docket Number	<i>Enlarged Prostate</i>
Sheet		of	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>PS</i>	<input checked="" type="checkbox"/>	CHENG JIANG et al., <u>Selenium - Induced Inhibition of Angiogenesis in Mammary Cancer at Chemopreventive Levels of Intake; Molecular Carcinogenesis; (1999); 213-225; v.26</u>	
	<input checked="" type="checkbox"/>	<del>CHENG JIANG et al. Monomethyl Selenium Specific Inhibition of MMP-2 and VEGF Expression: Implications for Angiogenic Switch Regulation, AMC Cancer Research Center - Denver, CO;</del>	
	<input checked="" type="checkbox"/>	<del>ENTREMED, INC., Entremed Phase II Clinical Trial Program Expands to Include Prostate Cancer <a href="http://www.entremed.com">http://www.entremed.com</a> author/date - unknown</del>	
	<input checked="" type="checkbox"/>	<del>ENTREMED, INC., 2-Methoxyestradiol An Orally Active Endogenous Inhibitor of Angiogenesis <a href="http://www.entremed.com">http://www.entremed.com</a> Author/date - unknown</del>	
	<input checked="" type="checkbox"/>	<del>ENTREMED, INC., <a href="http://www.entremed.com/products/small_molecules.htm">http://www.entremed.com/products/small_molecules.htm</a> Author/date - unknown</del>	
	<input checked="" type="checkbox"/>	<del>ENTREMED, INC., Entremed Scientists Report Discovery of New Angiogenesis Inhibitor <a href="http://www.entremed.com">http://www.entremed.com</a> Author/date - unknown</del>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**